Product Name :
MBP146-78
Description:
MBP146-78 is a potent and selective inhibitor of cGMP dependent protein kinases.
CAS:
188343-77-3
Molecular Weight:
335.42
Formula:
C21H22FN3
Chemical Name:
4-[2-(4-fluorophenyl)-5-(1-methylpiperidin-4-yl)-1H-pyrrol-3-yl]pyridine
Smiles :
CN1CCC(CC1)C1=CC(=C(N1)C1C=CC(F)=CC=1)C1C=CN=CC=1
InChiKey:
RBWNFHXBUDPAIO-UHFFFAOYSA-N
InChi :
InChI=1S/C21H22FN3/c1-25-12-8-16(9-13-25)20-14-19(15-6-10-23-11-7-15)21(24-20)17-2-4-18(22)5-3-17/h2-7,10-11,14,16,24H,8-9,12-13H2,1H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
MBP146-78 is a potent and selective inhibitor of cGMP dependent protein kinases.|Product information|CAS Number: 188343-77-3|Molecular Weight: 335.42|Formula: C21H22FN3|Chemical Name: 4-[2-(4-fluorophenyl)-5-(1-methylpiperidin-4-yl)-1H-pyrrol-3-yl]pyridine|Smiles: CN1CCC(CC1)C1=CC(=C(N1)C1C=CC(F)=CC=1)C1C=CN=CC=1|InChiKey: RBWNFHXBUDPAIO-UHFFFAOYSA-N|InChi: InChI=1S/C21H22FN3/c1-25-12-8-16(9-13-25)20-14-19(15-6-10-23-11-7-15)21(24-20)17-2-4-18(22)5-3-17/h2-7,10-11,14,16,24H,8-9,12-13H2,1H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 7.69 mg/mL (22.93 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|MBP146-78 displays a dose-dependent inhibition of T. gondii tachyzoites replicating inside HFFs, with an IC50 of 210 nM. The suppression of lytic parasite growth by MBP146-78 is reversible. Replacement of the medium with medium lacking MBP146-78, after treatment for up to 7 days at 2 μM, results in complete lysis of HFF cell monolayers.{{Sigma-2 receptor antagonist 1} medchemexpress|{Sigma-2 receptor antagonist 1} Sigma Receptor|{Sigma-2 receptor antagonist 1} Technical Information|{Sigma-2 receptor antagonist 1} Data Sheet|{Sigma-2 receptor antagonist 1} supplier|{Sigma-2 receptor antagonist 1} Epigenetic Reader Domain} MBP146-78 is neither toxic nor inhibitory to proliferating or confluent monolayers of HFFs at concentrations of up to 10 μM.{{Disitamab vedotin} MedChemExpress|{Disitamab vedotin} Antibody-Drug Conjugates (ADCs)|{Disitamab vedotin} Purity & Documentation|{Disitamab vedotin} In stock|{Disitamab vedotin} custom synthesis|{Disitamab vedotin} Autophagy} |In Vivo:|In infected mice that are treated with MBP146-78 at 50 mg/kg twice daily, parasites are undetectable throughout the 10-day treatment period in each of the tissues examined.PMID:23613863 However, samples from brain, spleen, and lung taken from infected treated mice reveal the presence of parasites after cessation of administration of MBP146-78, indicating that a transient asymptomatic parasite recrudescence occurs in all survivors. The ability of mice to control Toxoplasma infection after MBP146-78 treatment has been terminated suggests that the mouse immune system plays a synergistic role with chemotherapy in controlling the infection.|Products are for research use only. Not for human use.|